SCHEMBL1019577

SCHEMBL1019577

COc1ccc(S(=O)(=O)N(C)CCN(C)c2nc(Cc3ccc(F)c(C)c3)ns2)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
MMP1 P03956 1/20 0.37
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.37
ADAM17 P78536 1/20 0.37
TAS2R14 Q9NYV8 2/20 0.35
FFAR4 Q5NUL3 2/20 0.35
LMNA P02545 4/20 0.35
BMP1 P13497 2/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.35
TNF P01375 1/20 0.35
PDE4D Q08499 1/20 0.34
TP53 P04637 1/20 0.34
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020162 0.89 NOS2 (0.40) ALDH1A1MMP1MMP9MMP13ADAM17
SCHEMBL2012105 0.88 TAS2R14 (0.41) ALDH1A1MMP9MMP13TAS2R14LMNA
SCHEMBL2007365 0.87 LMNA (0.45) ALDH1A1LMNATSHRHTTRECQL
SCHEMBL1023771 0.87 ALDH1A1 (0.44) ALDH1A1FFAR4LMNARECQLSMN1; SMN2
SCHEMBL2002634 0.86 MGAT3 (0.42) ALDH1A1BMP1SMN1; SMN2MAPTTNF
SCHEMBL2003100 0.86 CNR2 (0.41) ALDH1A1MMP9SMN1; SMN2MAPTTP53
SCHEMBL2005838 0.85 MAPT (0.46) ALDH1A1LMNATSHRHTTRECQL
SCHEMBL1020526 0.85 BMP1 (0.41) ALDH1A1TAS2R14LMNABMP1SMN1; SMN2
SCHEMBL1018840 0.84 ALDH1A1 (0.39) ALDH1A1MMP1MMP9MMP13ADAM17
SCHEMBL1022400 0.84 ALDH1A1 (0.40) ALDH1A1TAS2R14LMNABMP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP ALDH1A1 608/4885MMP1 4297/4885MMP9 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.